Trop2-ADC药物在晚期乳腺癌中的安全性与疗效分析

2025-06-08 MedSci xAi 发表于广东省
本文深入分析Trop2-ADC药物在晚期乳腺癌治疗中的安全性与疗效,对比Dato-DXd、sacituzumab govitecan和SKB264的不良反应与生存期数据,提供最新临床研究证据与治疗建议。
Trop2-ADCs are safe and tolerable in advanced breast cancer, with differences in the toxicity profiles among different Trop2-ADC drugs. Overall, Dato-DXd demonstrates superior safety in terms of treatment-related adverse events (TRAEs) and hematological toxicity compared to other Trop2-ADCs, but gastrointestinal adverse reactions need to be monitored. Hematological toxicity and diarrhea are the most common adverse events for sacituzumab govitecan (SG), occurring at higher rates than with other Trop2-ADCs. Liver toxicity associated with SKB264 also requires attention. In terms of efficacy, the progression-free survival (PFS) of Dato-DXd and SKB264 is superior to that of SG, although SG appears to have an advantage in overall survival (OS).
AI
与梅斯小智对话

观星者应用

MedSearch MedSearch 医路规划 医路规划 数据挖掘 数据挖掘 文献综述 文献综述 文稿评审 文稿评审 课题设计 课题设计

科研工具

AI疑难疾病诊断 AI疑难疾病诊断 AI调研 AI调研 AI选刊 AI选刊 ICD-11智能查询 ICD-11智能查询 PUBMED文献推荐 PUBMED文献推荐 专业翻译 专业翻译 体检报告解读 体检报告解读 化验单智能识别 化验单智能识别 文本润色 文本润色 文献综述创作 文献综述创作 智能纠错 智能纠错 海外邮件智能回复 海外邮件智能回复 皮肤病自测 皮肤病自测 肌肤女神 肌肤女神 论文大纲 论文大纲 论文选题 论文选题